Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)

This study is testing a new investigational drug called EC5026 to see if it is safe, well tolerated, and potentially helpful for people with Parkinson's disease. It is an early-phase study focused on safety and initial signs of effectiveness. **You may be eligible if...** - You are between 50 and 80 years old - You have been diagnosed with Parkinson's disease (not caused by medications or other conditions) - Your Parkinson's is at or below stage 3 (mild to moderate) - You have been on a stable Parkinson's medication regimen for at least 30 days - You are not pregnant, breastfeeding, or planning to become pregnant during the study **You may NOT be eligible if...** - You have atypical Parkinson's or Parkinson's caused by medications, toxins, or other neurological conditions - You have significant dementia, psychosis, or severe mood disorders - You have recently had a heart attack, unstable heart condition, or serious kidney/liver/lung disease - You have used corticosteroids, cancer medications, or strong CYP3A4 interacting drugs recently - You have a history of hormone gland disorders (adrenal, pituitary, gonadal) - You have difficulty swallowing pills Talk to your doctor to see if this trial is right for you.